QCDR Measure:
AAO-11: Nonexudative Age-Related Macular Degeneration: Loss of Visual Acuity

National Quality Strategy Domain:
Effective Clinical Care

Measure Type:
Outcome

Description:
Percentage of patients with a diagnosis of nonexudative age-related macular degeneration and taking AREDS supplements with of loss of less than 0.3 logMar of visual acuity within the past 12 months.

Instructions:
This measure is to be reported a minimum of once per reporting period for patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with nonexudative age-related macular degeneration (in either one or both eyes) will submit this measure.

Denominator:
All patients aged 18 years of older with a diagnosis of nonexudative AMD and documentation of laterality (OD, OS, OU)

Denominator Criteria

Patients aged ≥ 18 years

AND

Diagnosis of nonexudative age-related macular degeneration

• Nonexudative age-related macular degeneration (ICD-10: H35.31)

AND

Taking antioxidant supplements
**Numerator:**

Patients with two or more recorded visual acuity values within the past 12 months; loss of visual acuity less than 0.3 logMar. Visual acuity of the eye with nonexudative AMD should be reported.

**Numerator Options:**

- **Performance Met:** Patients who achieved a loss in visual acuity of ≤ 0.3 logMar
- **Performance Not Met:** Patients who did not achieve a loss in visual acuity of ≤ 0.3 logMar

**Improvement Notation:**

Higher score indicates better performance